Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): $93.81

2.36 (+2.58%)

POWR Rating

Component Grades













HZNP Stock Summary

  • HZNP has a market capitalization of $20,489,153,020 -- more than approximately 88.79% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Horizon Therapeutics Public Ltd Co is reporting a growth rate of 589.84%; that's higher than 96.88% of US stocks.
  • As for revenue growth, note that HZNP's revenue has grown 69.26% over the past 12 months; that beats the revenue growth of 92.71% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be TECH, OMCL, RGEN, ECOM, and SPSC.
  • Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $93.81 52-week high $96.54
Prev. close $91.45 52-week low $31.60
Day low $92.53 Volume 678,332
Day high $95.88 Avg. volume 1,941,322
50-day MA $88.70 Dividend yield N/A
200-day MA $76.37 Market Cap 21.02B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio

Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$93.81$69.08 -24%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 48th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:

  • The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.31 years is 0.41%; that's better than 74.58% of cash flow producing equities in the Healthcare sector, where it is classified.
  • 95% of the company's capital comes from equity, which is greater than 82.41% of stocks in our cash flow based forecasting set.
  • The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately merely 17.55% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See PRAH, STE, AMED, ICLR, and SNY.

HZNP Latest News Stream

Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream

Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.

Yahoo | April 8, 2021

RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil

Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis & Rheumatology [doi.org/10.1002/art.41731].

Yahoo | April 7, 2021

Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.

Yahoo | March 30, 2021

Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership

Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as well as showcase their STEAM talents. Horizon is a biotechnology company that addresses critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.

Yahoo | March 29, 2021

Is Horizon Therapeutics (HZNP) A Good Stock to Short?

Carillon Tower Advisers, an investment management firm, published its fourth quarter 2020 “Carillon Eagle Small Cap Growth Fund” investor letter – a copy of which can be downloaded here. In the letter, the fund talked about their best and worst securities, together with their outlook for this year from an investment perspective. You can view the […]

Yahoo | March 25, 2021

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo 5.89%
3-mo 19.17%
6-mo 17.81%
1-year 193.62%
3-year 606.93%
5-year 534.71%
YTD 28.24%
2020 102.07%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.4394 seconds.